Johnson & Johnson (JNJ.US) announced its Q4 performance: Strong sales of cancer drugs help to resolve the "patent cliff" crisis.

Johnson & Johnson's fourth-quarter performance exceeded Wall Street expectations, due to strong sales of cancer drugs, which compensated for the decline in demand for the company's best-selling psoriasis treatment.

Zhitong FinanceJan 22 20:13

Netflix Rally Helps Boost S&P 500, Nasdaq

MT Newswires05:54

Health Care Roundup: Market Talk

WSJ05:50

Johnson & Johnson Options Spot-On: On January 22nd, 94,238 Contracts Were Traded, With 367.8K Open Interest

On January 22nd ET, $Johnson & Johnson(JNJ.US)$ had active options trading, with a total trading volume of 94,238 options for the day, of which put options accounted for 34.2% of the total

Futu News05:30

S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run

Benzinga05:23

Here's Why Johnson & Johnson (JNJ) Is Among the Highest Yielding Dividend Stocks In the Dow

Yahoo Finance04:52